# Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

> **NCT00718159** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Essential Thrombocythemia

## Interventions

- **DRUG:** LY573636-sodium

## Key facts

- **NCT ID:** NCT00718159
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718159, "Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00718159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*